Citius Pharmaceuticals Inc. (NASDAQ:CTXR) has announced that its CEO Myron Holubiak will offer a virtual presentation at the Life Sciences Investors Forum, including an update in the third Phase 3 pivotal Mino-Lok trial.
Citius CEO offers an update about its Phase 3 Mino-Lok solution study
The company is currently enrolling participants in the third phase of the Mino-Lok study. Holubiak will also offer an update on its option of licensing a proprietary stem cell therapy for the treatment of acute respiratory distress syndrome in patients having COVID-19. Recently the company indicated that the FDA had given an opinion about the proposal to study catheter compatibility for the Mino-Lok Therapy.
The company has also announced that it is offering health care providers free access to Mino-Lok therapy under the Expanded Access protocol. This is aimed at easing the burden related to the COVID-19 pandemic. Citius’ Mino-Lok solution can now treat an infected central venous catheter through the Expanded Access protocol. This will eliminate the need for a replacement procedure or removing an infected catheter, considering today’s challenges caused by the COVID-19 pandemic patients, hospital staff, and the hospital system in general stands to benefit significantly from the free access of the Mino-Lok therapy.
Citius waiting for clinical study results before marketing Mino-Lok solution
The CEO indicated that some investigators have indicated that if the FDA approves the Mino-Lok solution, they will use it, especially in the current circumstances. However, Holubiak stated that the company is waiting for the final results from its clinical study before marketing Mino-Lok. But for now, they are optimistic that the therapy can benefit patients and help ease the burden the healthcare system is facing. The CEO concluded that during this challenging period, they are ready to help in whichever way they can.
The Mino-Lok solution has been designed to treat patients having catheter-related bloodstream infections (CRBSIs). This is when used in combination with other antibiotics to enhance central venous access and minimize complications as well as associated morbidities to catheter reinsertion and removal.
